Sefaxersen Meets IgAN Phase Three Endpoint

Company Roche / Ionis Event Type Clinical Trial Data Readout Modality Antisense Oligonucleotide Asset Sefaxersen Target Complement Factor B Disease Area Primary IgA Nephropathy Summary Roche and Ionis reported that the 459-patient randomized IMAgINATION Phase 3 trial met its prespecified 37-week proteinuria endpoint in primary…